Last updated: June 30, 2023
Sponsor: University of British Columbia
Overall Status: Active - Recruiting
Phase
N/A
Condition
Spinal Cord Injuries
Cataplexy
Treatment
SCPP Management => 65 mmHg
Clinical Study ID
NCT03911492
H19-00805
Ages > 17 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Male or Female ≥ 17 (or the provincial age of majority - depending on local REBguidelines)
- Complete (AIS A) or incomplete (AIS B, C) acute traumatic spinal cord injury.
- Bony spinal levels between C0 and T12 inclusive.
- Blunt (non-penetrating) spinal cord injury treated either surgically or non-surgically
- Lumbar intrathecal catheter to be inserted as part of clinical hemodynamic managementand CSF sample collected within 48 hours of injury
- Initial blood sample collected within 24 hours of injury
Exclusion
Exclusion Criteria:
- Motor incomplete spinal cord injury AIS D (i.e. at least half (half or more) of thekey muscle functions below the neurological level of injury (NLI) have a muscle gradegreater than or equal to 3/5)
- Spinal cord injury with sensory deficit only (i.e. no motor deficit)
- Penetrating spinal cord injury (including gunshot wounds)
- Isolated radiculopathy
- Isolated cauda equina injury or spinal injury below L1
- Associated injury (soft tissue or bony) to the lumbar spine where the intrathecalcatheter would be placed
- Associated traumatic conditions that would interfere with the outcome assessment (e.g., traumatic brain injury, chest, pelvis, abdomen, or femur injury requiringoperative intervention)
- Pre-existing neurodegenerative disorder, such as Parkinson's disease, Alzheimer'sdisease, Huntington's disease, multiple sclerosis, amyotrophic lateral sclerosis
- Pre-existing thromboembolic disease or coagulopathy, such as hemophilia, vonWillebrand disease
- Presence of systemic disease that might interfere with patient safety, compliance orevaluation of the condition under study (e.g., clinically significant cardiac disease,HIV, Hep B or C) HTLV-1
- Pre-existing inflammatory or autoimmune disorder (e.g. rheumatoid arthritis, systemiclupus, psoriasis, or ankylosing spondylitis
- Any other medical condition that in the investigator's opinion would render theprotocol procedures dangerous or impair the ability of the patient to receive protocoltherapy
- Female patients who are pregnant
Study Design
Total Participants: 100
Treatment Group(s): 1
Primary Treatment: SCPP Management => 65 mmHg
Phase:
Study Start date:
August 31, 2019
Estimated Completion Date:
December 31, 2025
Study Description
Connect with a study center
Vancouver General Hospital
Vancouver, British Columbia V5Z 1M9
CanadaActive - Recruiting
Halifax Infirmary - QEII
Halifax, Nova Scotia B3K 4N1
CanadaActive - Recruiting
St. Michael's Hospital
Toronto, Ontario M5B 1W8
CanadaActive - Recruiting
Hopital Du Sacre-Coeur de Montreal
Montreal, Quebec H4J1C5
CanadaActive - Recruiting
Zuckerberg San Francisco General Hospital and Trauma Center
San Francisco, California 94110
United StatesActive - Recruiting
University of Nebraska Medical Center
Omaha, Nebraska 68198
United StatesActive - Recruiting
University of New Mexico Health Sciences Center
Albuquerque, New Mexico 87131
United StatesActive - Recruiting
University Pittsburgh Medical Center
Pittsburgh, Pennsylvania 15213
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.